Saqqur Maher, Tsivgoulis Georgios, Nicoli Francois, Skoloudik David, Sharma Vijay K, Larrue Vincent, Eggers Jürgen, Perren Fabienne, Charalampidis Paris, Storie Dale, Shuaib Ashfaq, Alexandrov Andrei V
From the Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.
J Neuroimaging. 2014 May-Jun;24(3):209-20. doi: 10.1111/jon.12026. Epub 2013 Apr 22.
To assess the evidence on the safety and efficacy of sonothrombolysis in acute stroke.
Electronic databases and grey literature were searched under different MeSH terms from 1970 to present.
Randomized control trials (RCTs) and case control studies (CCSs) on sonolysis and sonothrombolysis alone or with microsphere in acute stroke patients (>18 old). Outcome measures included complete recanalization (CR) at 1-2 and 24 hours, 3 months modified Rankin Scale (mRS), and symptomatic intracerebral hemorrhage (sICH). Data was extracted to Review Manager software.
Fifty-seven studies were retrieved and analyzed. Ten studies (7 RCTs and 3 CCSs) were included in our meta-analysis, which revealed that sonolysis and sonothrombolysis are safe (OR of sICH: 1.14; 95% confidence interval (CI): 0.56- 2.34;P=0.71) and effective (OR of CR at 1-2 hours: 2.95;95% CI: 1.81-4.81;P<0.00001) and have more than two-fold higher likelihood of favourable long-term outcome (3-month mRS 0-2; OR: 2.20; CI:1.52-3.19;P<0.0001). Further subgroup analysis based on the presence of microsphere revealed that it is safe (OR of sICH: 1.18; CI:0.433.24;P=0.75) and effective (OR of CR: 2.61; CI: 1.36-4.99;P=0.004). Subgroup analysis based on sonolysis revealed to be safe and effective.
This novel treatment appears safe and effective. The evidence of microsphere as an enhancement of sonothrombolysis is evolving.
评估超声溶栓治疗急性卒中的安全性和有效性证据。
从1970年至今,使用不同的医学主题词对电子数据库和灰色文献进行检索。
针对急性卒中患者(年龄>18岁)单独使用超声溶解或超声溶栓以及联合微球的随机对照试验(RCT)和病例对照研究(CCS)。结局指标包括1-2小时和24小时的完全再通(CR)、3个月改良Rankin量表(mRS)以及症状性颅内出血(sICH)。数据提取至Review Manager软件。
检索并分析了57项研究。10项研究(7项RCT和3项CCS)纳入我们的荟萃分析,结果显示超声溶解和超声溶栓是安全的(sICH的OR值:1.14;95%置信区间(CI):0.56 - 2.34;P = 0.71)且有效(1-2小时CR的OR值:2.95;95% CI:1.81 - 4.81;P < 0.00001),长期预后良好(3个月mRS 0-2)的可能性高出两倍多(OR值:2.20;CI:1.52 - 3.19;P < 0.0001)。基于微球存在情况的进一步亚组分析显示其是安全的(sICH的OR值:1.18;CI:0.43 - 3.24;P = 0.75)且有效(CR的OR值:2.61;CI:1.36 - 4.99;P = 0.004)。基于超声溶解的亚组分析显示是安全且有效的。
这种新型治疗方法似乎安全有效。微球作为超声溶栓增强剂的证据仍在不断发展。